Design and Construction of Tumor Precision Medicine Knowledge Database

doi:10.13523/j.cb.20180506

China Biotechnology

2018, Vol. 38

Issue (5): 40-46 DOI: 10.13523/j.cb.20180506

Design and Construction of Tumor Precision Medicine Knowledge Database

Ling WANG¹,Xin CHEN^2,^*

1 College of Chemical and Biological Engineering, Zhejiang University, Hangzhou 310027, China
2 Institute of Pharmaceutical Biotechnology, Zhejiang University, Hangzhou 310058, China

Download:

HTML

PDF(846KB) HTML
Export: BibTeX | EndNote (RIS)

Abstract

Objective:To integrate substantial but scattered state-of-the-art precision medicine knowledge and form a systematic knowledge network, to support clinical application of individual omics data, aiming at precision medication recommendations.Methods:The database was constructed using MySQL. Precision medicine knowledge from FDA companion diagnosis, NCCN guidelines, My Cancer Genome and GDSC was manually collected in a unified format after being standardized and structured.Results:The tumor precision medicine knowledge base (PMKB) was successfully designed and constructed and has already collected 1 940 clinical directives, covering 14 kinds of variations.Conclusion:PMKB collects information relating tumor mutations and therapeutic strategies, which can provide personalized treatments of reference. PMKB is also the base of constructing a clinical decision support system of precision medicine.

Key words： Tumor Precision medicine Database Omics data

Received: 12 October 2017 Published: 05 June 2018

ZTFLH:

Q354

Corresponding Authors: Xin CHEN

	Service
	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	Ling WANG
	Xin CHEN

Cite this article:

Ling WANG,Xin CHEN. Design and Construction of Tumor Precision Medicine Knowledge Database. China Biotechnology, 2018, 38(5): 40-46.

URL:

https://manu60.magtech.com.cn/biotech/10.13523/j.cb.20180506 OR https://manu60.magtech.com.cn/biotech/Y2018/V38/I5/40

Fig.1 Entity relationship diagram of PMKB

Table 1 Clinical directive table

Fig.2 Logic decomposition illustration of complex indication

Table 2 Indication complex table

Table 3 Complex indication components table

Table 4 Indication atomic table

Table 5 Therapeutic strategy table

Table 6 Therapeutic strategy components table

Table 7 The number of clinical directives collected in PMKB

Table 8 The number of records collected in PMKB

Fig.3 Illustration of precision medication searching system


[1]	Stratton M R, Campbell P J, Futreal P A . The cancer genome. Nature, 2009,458(7239):719-724. doi: 10.1038/nature07943

[2]	付文华, 钱海利, 詹启敏 . 中国精准医学发展的需求和任务. 中国生化药物杂志, 2016,36(4):1-4.

[2]	Fu W H, Qian H L, Zhan Q M . Precision medicine in China. Chinese Journal of Biochemical Pharmaceutics, 2016,36(4):1-4.

[3]	Garraway L A, Verweij J, Ballman K V . Precision oncology: an overview. Journal of Clinical Oncology, 2013,31(15):1803-1805. doi: 10.1200/JCO.2013.49.4799

[4]	Sorich M J, Wiese M D, Rowland A , et al. Extended RAS mutations and anti-EGFR monoclonal antibody survival benefit in metastatic colorectal cancer: a meta-analysis of randomized, controlled trials. Annals of Oncology, 2015,26(1):13-21. doi: 10.1093/annonc/mdu378 pmid: 25115304

[5]	Allegra C J, Rumble R B, Richard L S , et al. Extended RAS gene mutation testing in metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy: American society of clinical oncology provisional clinical opinion update 2015 summary. Journal of Clinical Oncology, 2016,34(2):179-185.

[6]	Ali S M, Hensing T, Schrock A B , et al. Comprehensive genomic profiling identifies a subset of crizotinib-responsive ALK-rearranged non-small cell lung cancer not detected by fluorescence in situ hybridization. Oncologist, 2016,21(6):762-770. doi: 10.1634/theoncologist.2015-0497

[7]	Rankin A, Klempner S J, Erlich R , et al. Broad detection of alterations predicted to confer Lack of benefit from EGFR antibodies or sensitivity to targeted therapy in advanced colorectal cancer. Oncologist, 2016,21(11):1306-1314. doi: 10.1634/theoncologist.2016-0148 pmid: 27682134

[8]	Boussemart, Wang A , Wong M K K, et al. Hybrid-capture based genomic profiling identifies BRAF V600 and non-V600 alterations in melanoma samples negative by prior testing. Annals of Oncology, 2017,28(suppl_5):v428-v448. doi: 10.1093/annonc/mdx377.020

[9]	Kusnoor S V, Koonce T Y, Levy M A , et al. My cancer genome: evaluating an educational model to introduce patients and caregivers to precision medicine information. AMIA Joint Summits on Translational Science, 2016,( 2016):112-121. pmid: 5001739

[10]	Levy M, Lovly C, Horn L , et al. My cancer genome: Web-based clinical decision support for genome-directed lung cancer treatment. Journal of Clinical Oncology, 2011,29(15 suppl):7576. doi: 10.1093/annonc/mdr431

[11]	Iorio F, Knijnenburg T, Vis D , et al. A landscape of pharmacogenomic interactions in cancer. Cell, 2016,166(3):740. doi: 10.1016/j.cell.2016.06.017 pmid: 27397505

[12]	Castaneda C, Nalley K, Mannion C , et al. Clinical decision support systems for improving diagnostic accuracy and achieving precision medicine. Journal of Clinical Bioinformatics, 2015,5(1):4. doi: 10.1186/s13336-015-0019-3 pmid: 4381462

[13]	Fridlyand J, Simon R M, Walrath J C , et al. Considerations for the successful co-development of targeted cancer therapies and companion diagnostics. Nature Reviews Drug Discovery, 2013,12(10):743. doi: 10.1038/nrd4101 pmid: 24008432

[14]	Mansfield E A . FDA perspective on companion diagnostics: an evolving paradigm. Clinical Cancer Research, 2014,20(6):1453-1457. doi: 10.1158/1078-0432.CCR-13-1954 pmid: 24634468

[15]	National Comprehensive Cancer Network. About NCCN.[2017-12-27]. .

[16]	National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: non-small cell lung.[2017-12-27]. .

[17]	Vanderbilt-Ingram Cancer Center, My Cancer Genome (Website Index). [2017-12-27]..

[18]	Yang W, Soares J, Greninger P , et al. Genomics of drug sensitivity in cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cells. Nucleic Acids Research, 2013,41:D955-D961.

[19]	Al-Haddad M A, Friedlin J, Kesterson J , et al. Natural language processing for the development of a clinical registry: a validation study in intraductal papillary mucinous neoplasms. HPB, 2010,12(10):688-695. doi: 10.1111/j.1477-2574.2010.00235.x

[20]	Koh H C, Tan G . Data mining applications in healthcare. Journal of Healthcare Information Management, 2005,19(2):64-72. doi: 10.4314/ijonas.v5i1.49926 pmid: 15869215

[1]	ZHAO Meng-ze,LI Feng-zhi,WANG Peng-yin,LI Jian,XU Han-mei. Research Progress of Dual-target Blocking Therapy of PD-L1 and VEGF[J]. China Biotechnology, 2021, 41(9): 71-77.

[2]	LV Hui-zhong,ZHAO Chen-chen,ZHU Lian,XU Na. Progress of Using Exosome for Drug Targeted Delivery in Tumor Therapy[J]. China Biotechnology, 2021, 41(5): 79-86.

[3]	YUAN Bo,WANG Jie-wen,KANG Guang-bo,HUANG He. Research Progress and Application of Bispecific Nanobody[J]. China Biotechnology, 2021, 41(2/3): 78-88.

[4]	DENG Rui,ZENG Jia-li,LU Xue-mei. *Screening and Structure-activity Relationship Analysis of Anti-tumor Derived Peptides Based on Musca domestica* cecropin**[J]. China Biotechnology, 2021, 41(11): 14-22.

[5]	LIN Shi-xin,LIU Dong-chen,LEI Yun,XIONG Sheng,XIE Qiu-ling. Screening, Expression and Specificity Detection of Anti-TNF-α Nanobody[J]. China Biotechnology, 2020, 40(7): 15-21.

[6]	YANG Wei,SONG Fang-xiang,WANG Shuai,ZHANG Li,WANG Hong-xia,LI Yan. Preparation and Application of Janus Nanoparticles in Drug Delivery System[J]. China Biotechnology, 2020, 40(7): 70-81.

[7]	ZHANG Bao-hui,XIONG Hua-long,ZHANG Tian-ying,YUAN Quan. Research Progress on Vesicular Stomatitis Virus-based Oncolytic Virotherapy[J]. China Biotechnology, 2020, 40(6): 53-62.

[8]	TONG Mei,CHENG Yong-qing,LIU Jin-yi,XU Chen. Construction of a Strain for Promoting Production of Small Molecule Antibodies in Periplasmic Space of Escherichia coli[J]. China Biotechnology, 2020, 40(5): 48-56.

[9]	DAI Qi-nan,ZHANG Jing-hong. Advances in Molecular Mechanisms Related to Tumor Multi-drug Resistance, Autophagy, DNA Repair and Tumor Stem Cells[J]. China Biotechnology, 2020, 40(4): 69-77.

[10]	QIAN Ying,QIAN Chen,BAI Xiao-qing,WANG Jing-jing. Application of Adjuvant in Cancer Immunotherapy[J]. China Biotechnology, 2020, 40(3): 96-103.

[11]	XIAO Xue-jun,TANG Qi,XINHUA Nabi. CAR-T Therapy Targeting Tumor Microenvironment[J]. China Biotechnology, 2020, 40(12): 67-74.

[12]	HE Xun,ZHANG Peng,ZHANG Jun-xiang. Progress in the Construction and Application of Organoids[J]. China Biotechnology, 2020, 40(12): 82-87.

[13]	ZHU Yongzhao,TAO Jin,REN Meng-meng,XIONG Ran,HE Ya-qin,ZHOU Yu,LU Zhen-hui,DU Yong,YANG Zhi-hong. Autophagy Protects Against Apoptosis of Human Placental Mesenchymal Stem Cells of Fetal Origin Induced by Tumor Necrosis Fator-α[J]. China Biotechnology, 2019, 39(9): 62-67.

[14]	LIU Yan,DAI Peng,ZHU Yun-feng. Research Progress of Exosome as Tumor Marker[J]. China Biotechnology, 2019, 39(8): 74-79.

[15]	Hai-yin LV,Teng-fei WANG,Ren-jun PEI. Progress in Aptamer Based Tumor Immunotherapy[J]. China Biotechnology, 2019, 39(6): 55-61.

Viewed

Full text

Abstract

Cited

Shared

Discussed